Get the Stockscreener App
232.39
1.25%
2.88
After Hours:
232.39
Penumbra Inc stock is traded at $232.39, with a volume of 413.82K.
It is up +1.25% in the last 24 hours and up +19.34% over the past month.
Penumbra Inc develops and manufactures medical devices for the neurovascular and peripheral vascular markets. Its products are sold to hospitals and are developed for use by specialist physicians. The neurovascular product category contributes to the majority of revenue. Within the neurovascular business, the firm offers products for neurovascular access, ischemic stroke, neurovascular embolization, and neurosurgical tool markets. In the peripheral vascular business, the firm sells devices related to peripheral embolization and peripheral thrombectomy. Penumbra generates the majority of its revenue in the United States.
See More
Previous Close:
$229.51
Open:
$229.01
24h Volume:
413.82K
Relative Volume:
1.02
Market Cap:
$8.92B
Revenue:
$1.13B
Net Income/Loss:
$14.23M
P/E Ratio:
225.62
EPS:
1.03
Net Cash Flow:
$110.67M
1W Performance:
+10.86%
1M Performance:
+19.34%
6M Performance:
+11.43%
1Y Performance:
+17.45%
1-Day Range:
$228.65
$235.47
1-Week Range:
$207.58
$237.46
52-Week Range:
$148.00
$277.34
Penumbra Inc Stock (PEN) Company Profile
Name
Penumbra Inc
Sector
Industry
Phone
(510) 995-2486
Address
ONE PENUMBRA PLACE, ALAMEDA, CA
Penumbra Inc Stock (PEN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-06-23 | Initiated | Morgan Stanley | Equal-Weight |
| Jul-19-23 | Initiated | Robert W. Baird | Outperform |
| Mar-29-23 | Downgrade | Needham | Buy → Hold |
| Jan-30-23 | Initiated | Piper Sandler | Overweight |
| Nov-04-22 | Upgrade | Citigroup | Neutral → Buy |
| Oct-12-22 | Initiated | Jefferies | Buy |
| Oct-05-22 | Downgrade | Citigroup | Buy → Neutral |
| Sep-09-22 | Upgrade | Needham | Hold → Buy |
| Jul-18-22 | Initiated | RBC Capital Mkts | Outperform |
| Apr-19-22 | Initiated | Deutsche Bank | Buy |
| Mar-08-22 | Initiated | Needham | Hold |
| Sep-16-21 | Initiated | Truist | Buy |
| Jun-04-21 | Upgrade | BTIG Research | Neutral → Buy |
| Dec-16-20 | Downgrade | BTIG Research | Buy → Neutral |
| Oct-07-20 | Resumed | Canaccord Genuity | Buy |
| Sep-29-20 | Initiated | BTIG Research | Buy |
| Sep-08-20 | Downgrade | BofA Securities | Buy → Neutral |
| Mar-05-20 | Initiated | Citigroup | Buy |
| Jun-13-19 | Reiterated | BofA/Merrill | Buy |
| May-30-19 | Upgrade | JP Morgan | Neutral → Overweight |
| May-21-19 | Initiated | William Blair | Outperform |
| Oct-29-18 | Resumed | BofA/Merrill | Buy |
| Oct-08-18 | Initiated | RBC Capital Mkts | Outperform |
| Feb-21-18 | Initiated | William Blair | Outperform |
| Jan-02-18 | Downgrade | JP Morgan | Overweight → Neutral |
| Nov-30-15 | Reiterated | Canaccord Genuity | Buy |
| Oct-13-15 | Initiated | Wells Fargo | Outperform |
View All
Penumbra Inc Stock (PEN) Latest News
Penumbra has positive data for computer-assisted vacuum thrombectomy system - Mass Device
Penumbra reports shorter stays, fewer PE complications with CAVT - Investing.com
Penumbra's CAVT Tech Shows 35% Shorter Hospital Stays, 3x Fewer PE Complications | PEN Stock News - StockTitan
4,000 Shares in Penumbra, Inc. (NYSE:PEN) Purchased by AlphaCentric Advisors LLC - MarketBeat
Penumbra's SWOT analysis: innovation drives growth amid market challenges - Investing.com India
Penumbra shares rise as Canaccord lifts target, keeps at Buy list - Investing.com
Implied Volatility Surging for Penumbra (PEN) Stock Options - Yahoo Finance
Penumbra revenue jumps 11.1% to USD 301M in Q3 2024 - Medical Buyer
Equities Analysts Issue Forecasts for Penumbra Q1 Earnings - MarketBeat
Penumbra, Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For Next Year - Yahoo Finance
Is Penumbra, Inc.'s (NYSE:PEN) Recent Stock Performance Influenced By Its Fundamentals In Any Way? - Simply Wall St
Penumbra Inc (PEN) Shares Up 3.26% on Nov 1 - GuruFocus.com
Penumbra Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance
Research Analysts Set Expectations for Penumbra Q4 Earnings - MarketBeat
Penumbra, Inc. (NYSE:PEN) Q3 2024 Earnings Call Transcript - Insider Monkey
Exploring the Future of Virtual Reality: Market Overview, Trends, Analysis & Key Players - GlobeNewswire Inc.
Penumbra Inc (PEN) Trading 4.48% Higher on Oct 31 - GuruFocus.com
Penumbra Inc (PEN) Q3 2024 Earnings: Revenue Hits $301 Million, Surpassing Estimates - GuruFocus.com
Earnings call: Penumbra reports Q3 revenue rise, U.S. thrombectomy growth By Investing.com - Investing.com Canada
Earnings call: Penumbra reports Q3 revenue rise, U.S. thrombectomy growth - Investing.com
Penumbra stock maintains buy rating with BTIG despite price target cut - Investing.com
Penumbra Q3 Earnings Beat, Margins Expand, Stock Up in After Market - MSN
Piper Sandler Raises Penumbra (NYSE:PEN) Price Target to $235.00 - MarketBeat
Needham & Company LLC Reaffirms Hold Rating for Penumbra (NYSE:PEN) - MarketBeat
Penumbra (PEN) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates - MSN
Penumbra price target raised to $235 from $225 at Piper Sandler - TipRanks
Penumbra stock outlook brightens on share gains and robust VTE growth - Investing.com India
Congress Asset Management Co. Cuts Stock Position in Penumbra, Inc. (NYSE:PEN) - MarketBeat
Penumbra Inc (PEN) Q3 2024 Earnings Call Highlights: Strong U.S. Growth Amid International Challenges - GuruFocus.com
Penumbra Inc (PEN) Q3 2024 Earnings Call Highlights: Strong U.S. ... - Yahoo Finance
Penumbra price target raised to $248 from $244 at Baird - TipRanks
Penumbra: Q3 Earnings Snapshot - Milford Mirror
Penumbra, Inc. Sees Strong Q3 Revenue Growth - TipRanks
Penumbra Inc earnings beat by $0.16, revenue topped estimates - Investing.com
Penumbra (PEN) Q3 Earnings and Revenues Top Estimates - Yahoo Finance
Penumbra, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Penumbra still sees 2024 revenue $1.18B-$1.20B, consensus $1.19B - TipRanks
Penumbra, Inc. Reports Third Quarter 2024 Financial Results - PR Newswire
Penumbra (FRA:0P8) 5-Year Dividend Growth Rate : 0.00% (As of Jun. 2024) - GuruFocus.com
Penumbra shares retain hold rating amid Thunderbolt study progress - Investing.com India
Penumbra shares retain hold rating amid Thunderbolt study progress By Investing.com - Investing.com Australia
Penumbra (NYSE:PEN) Stock Rating Reaffirmed by Needham & Company LLC - MarketBeat
E. Ohman J or Asset Management AB Buys 4,000 Shares of Penumbra, Inc. (NYSE:PEN) - MarketBeat
Key Takeaways From Penumbra Analyst Ratings - Benzinga
Penumbra CEO Adam Elsesser sells $3.07 million in stock By Investing.com - Investing.com Australia
Penumbra CEO Adam Elsesser sells $3.07 million in stock - Investing.com
Insider Selling: Penumbra, Inc. (NYSE:PEN) CEO Sells 15,000 Shares of Stock - MarketBeat
Penumbra (PEN) Earnings Expected to Grow: What to Know Ahead of Next Week's Release - Yahoo Finance
Allspring Global Investments Holdings LLC Acquires 3,973 Shares of Penumbra, Inc. (NYSE:PEN) - MarketBeat
Penumbra (PEN) Scheduled to Post Earnings on Wednesday - MarketBeat
Ischemic Neurological Interventional Medical Devices Market - openPR
Penumbra Inc Stock (PEN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.47%
1.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):